Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 2FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 53Colorectal Neoplasms 42Neoplasms 37Lung Neoplasms 22Breast Neoplasms 15Colonic Neoplasms 14Colonic Polyps 13Rare Diseases 9Carcinoma, Non-Small-Cell Lung 9Carcinoma, Hepatocellular 9Ovarian Neoplasms 7Adenoma 7Pulmonary Disease, Chronic Obstructive 6Neoplasm Metastasis 6Heart Failure 6Head and Neck Neoplasms 6Rectal Neoplasms 5Motor Activity 5Liver Neoplasms 5Fibrosis 5Carcinoma, Squamous Cell 5Barrett Esophagus 5Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Neoplasms by Site 4Mental Disorders 4Lymphoma 4Lung Diseases 4Leukemia 4Esophageal Neoplasms 4

Interventions

2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
FED × Prostate Cancer Diagnosis × Clear all
NCT05820724 2023-04-24

PSMA PET Scan and mpMRI for Prostate Cancer Detection

VA Greater Los Angeles Healthcare System

Phase 2 Unknown
100 enrolled
Genitourinary

Prostate Cancer Diagnosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡